BRUKER CORP BRKR
We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels. Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. Our products and solutions address the rapidly evolving needs of a diverse array of customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology. Our technology platforms include magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, and molecular spectroscopy technologies. We are enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research and offer differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Our corporate headquarters are located in Billerica, Massachusetts. We maintain major technical and manufacturing centers in Europe and North America and have sales offices located throughout the world.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.44B | $3.37B | $2.96B | $2.53B | $2.42B | $1.99B | $2.07B | $1.90B | $1.77B | $1.61B |
| Cost of revenue | $1.86B | $1.72B | $1.45B | $1.23B | $1.21B | $1.05B | $1.08B | $995.6M | $949.9M | $866.0M |
| Gross profit | $1.58B | $1.65B | $1.51B | $1.31B | $1.21B | $939.8M | $995.3M | $900.0M | $816.0M | $745.3M |
| R&D | $395.2M | $376.5M | $294.8M | $235.9M | $220.8M | $198.0M | $187.7M | $173.4M | $161.6M | $147.9M |
| SG&A | $946.5M | $893.8M | $729.4M | $607.4M | $561.2M | $468.6M | $500.2M | $444.7M | $415.2M | $389.8M |
| Total operating expenses | $1.51B | $1.40B | $1.08B | $873.0M | $796.3M | $691.5M | $694.4M | $637.6M | $596.5M | $563.5M |
| Operating income | $68.2M | $253.1M | $436.9M | $432.7M | $413.3M | $248.3M | $300.9M | $262.4M | $219.5M | $181.8M |
| Interest expense | $60.3M | $47.9M | $16.4M | $16.1M | $14.3M | $14.4M | $16.0M | $12.6M | $15.4M | $13.2M |
| Pre-tax income | $22.0M | $206.9M | $544.2M | $413.9M | $393.6M | $225.8M | $280.4M | $244.7M | $197.8M | $177.6M |
| Income tax | $29.3M | $91.4M | $117.7M | $116.4M | $113.0M | $64.4M | $82.4M | $63.7M | $117.5M | $23.1M |
| Net income | -$8.3M | $113.8M | $428.5M | $298.5M | $280.6M | $157.8M | $197.2M | $179.7M | $78.6M | $153.6M |
| EPS, basic | -0.15 | 0.76 | 2.92 | 2.00 | 1.83 | 1.03 | 1.27 | 1.15 | 0.50 | 0.95 |
| EPS, diluted | -0.15 | 0.76 | 2.90 | 1.99 | 1.81 | 1.02 | 1.26 | 1.14 | 0.49 | 0.95 |
| Shares, diluted (wtd. avg.) | $151.8M | $149.5M | $147.2M | $149 | $153 | $155 | $157 | $157.2M | $159.1M | $162.2M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $298.8M | $183.4M | $491.6M | $648.7M | $1.07B | $685.5M | $681.9M | $326.3M | $328.9M | $345.9M |
| Short-term investments | — | — | — | $0 | $100.0M | $50.0M | $6.6M | $0 | $114.2M | — |
| Receivables | $544.9M | $565.5M | $492.0M | $472.7M | $416.9M | $335.3M | $362.2M | $357.2M | $319.3M | $243.9M |
| Inventory | $1.09B | $1.07B | $968.3M | $800.1M | $710.1M | $692.3M | $577.2M | $509.6M | $486.2M | $440.4M |
| Total current assets | $2.21B | $2.05B | $2.16B | $2.11B | $2.47B | $1.93B | $1.80B | $1.30B | $1.36B | $1.28B |
| Property, plant and equipment | $744.8M | $669.3M | $599.7M | $487.0M | $406.1M | $395.5M | $306.1M | $270.6M | $266.5M | $239.1M |
| Goodwill | $1.55B | $1.51B | $582.6M | $457.6M | $339.5M | $320.4M | $293.0M | $275.7M | $169.8M | $130.6M |
| Other intangibles | $899.6M | $912.5M | $330.5M | $270.9M | $211.8M | $229.1M | $233.2M | $218.7M | $82.4M | $69.7M |
| Total assets | $6.24B | $5.81B | $4.25B | $3.61B | $3.65B | $3.05B | $2.77B | $2.13B | $1.95B | $1.81B |
| Accounts payable | $215.9M | $234.1M | $202.7M | $178.4M | $147.4M | $134.6M | $118.4M | $104.5M | $90.8M | $86.1M |
| Total current liabilities | $1.28B | $1.28B | $1.20B | $914.3M | $938.5M | $791.9M | $645.6M | $599.3M | $524.5M | $524.7M |
| Long-term debt | $1.85B | $2.06B | $1.16B | $1.20B | $1.22B | $842.3M | $812.8M | $322.6M | — | — |
| Total liabilities | $3.73B | $3.99B | $2.84B | $2.48B | — | — | — | — | — | — |
| Retained earnings | $2.36B | $2.41B | $2.32B | $1.93B | $1.66B | $1.41B | $1.27B | $1.10B | $942.0M | $885.2M |
| Total equity | $2.46B | $1.78B | $1.39B | $1.13B | $1.08B | $974.3M | $917.1M | $905.1M | $733.5M | $693.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $134.1M | $251.3M | $350.1M | $274.4M | $282.4M | $332.2M | $213.4M | $239.7M | $154.4M | $130.8M |
| Depreciation and amortisation | $220.3M | $183.8M | $114.9M | $88.8M | $89.1M | $80.4M | $75.6M | $64.9M | $63.9M | $54.3M |
| Stock-based compensation | $20.2M | $25.3M | $30.9M | $27.7M | $17.2M | $16.0M | $9.6M | $11.3M | $11.0M | $9.4M |
| Capital expenditure | $90.8M | $115.3M | $106.9M | $129.2M | $92.0M | $97.2M | $12.3M | $49.2M | $43.7M | $37.1M |
| Investing cash flow | -$196.5M | -$1.76B | -$326.0M | -$251.6M | -$192.4M | -$192.7M | -$158.4M | -$123.4M | -$30.2M | -$21.8M |
| Financing cash flow | $135.1M | $1.23B | -$193.4M | -$415.3M | $318.7M | -$161.6M | $300.0M | -$112.4M | -$159.0M | -$27.9M |
| Dividends paid | $22.8M | $30.2M | $29.4M | $29.8M | $24.2M | $24.6M | $25.0M | $25.1M | $25.4M | $25.8M |
| Buybacks | $10.0M | $0 | $152.3M | $263.1M | $153.3M | $123.2M | $142.3M | $200.0K | $152.2M | $160.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151305.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| TXG | 10x Genomics, Inc. | $8.14B | — | 5.2% |